229 related articles for article (PubMed ID: 17910546)
1. Quality indicators for the care of breast cancer in vulnerable elders.
Naeim A; Sawhney R; MacLean CH; Sanati H
J Am Geriatr Soc; 2007 Oct; 55 Suppl 2():S258-69. PubMed ID: 17910546
[No Abstract] [Full Text] [Related]
2. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological characteristics of breast cancer.
Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
[TBL] [Abstract][Full Text] [Related]
4. An unusual triple-negative breast carcinoma.
Shousha S; Peston D; Gojis O; Palmieri C
Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156
[No Abstract] [Full Text] [Related]
5. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
Wang YJ; Wang N; Wang B; Qin WX; Xue CY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
[TBL] [Abstract][Full Text] [Related]
6. Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer.
Grewal J; Zhou H; Factor R; Kesari S
J Clin Oncol; 2010 May; 28(13):e200-2. PubMed ID: 20124173
[No Abstract] [Full Text] [Related]
7. Overview of breast cancer.
Watkins EJ
JAAPA; 2019 Oct; 32(10):13-17. PubMed ID: 31513033
[TBL] [Abstract][Full Text] [Related]
8. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer in the oldest old (≥ 89 years): Tumor characteristics, treatment choices, clinical outcomes and literature review.
Di Lascio S; Tognazzo E; Bigiotti S; Bonollo M; Costa A; Pagani O; Meani F
Eur J Surg Oncol; 2021 Apr; 47(4):796-803. PubMed ID: 33097334
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres.
Angarita FA; Chesney T; Elser C; Mulligan AM; McCready DR; Escallon J
Eur J Surg Oncol; 2015 May; 41(5):625-34. PubMed ID: 25727372
[TBL] [Abstract][Full Text] [Related]
11. Surgical management of lobular carcinoma from a national screening program: a retrospective analysis.
Sharma SD; Barry M; O'Reilly EA; Kell MR
Eur J Surg Oncol; 2015 Jan; 41(1):79-85. PubMed ID: 25441933
[TBL] [Abstract][Full Text] [Related]
12. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and morphological features and treatment for lobular breast cancer].
Tabagua TT; Semiglazov VV; Bus'ko EA; Semiglazova TIu; Voroshnikov VV
Vopr Onkol; 2013; 59(3):386-9. PubMed ID: 23909043
[TBL] [Abstract][Full Text] [Related]
14. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
Mehta RS
J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
[No Abstract] [Full Text] [Related]
16. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Altundag K; Bulut N; Sari E; Harputluoglu H
Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
[No Abstract] [Full Text] [Related]
17. Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
Ouldamer L; Bendifallah S; Chas M; Boivin L; Bedouet L; Body G; Ballester M; Daraï E
Eur J Cancer; 2016 Dec; 69():102-109. PubMed ID: 27821312
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in breast cancers.
Masood S
Womens Health (Lond); 2016 Sep; 12(5):480-491. PubMed ID: 27885165
[TBL] [Abstract][Full Text] [Related]
19. Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.
Cutuli B; Dalenc F; Cottu PH; Gligorov J; Guastalla JP; Petit T; Amrate A
Cancer Radiother; 2015 Aug; 19(5):295-302. PubMed ID: 26188735
[TBL] [Abstract][Full Text] [Related]
20. [1st revision of the National Consensus on Breast Cancer Treatment].
Consenso Nacional sobre Tratamiento del Cáncer Mamario
Ginecol Obstet Mex; 2002 Jul; 70():349-60. PubMed ID: 12221911
[No Abstract] [Full Text] [Related]
[Next] [New Search]
